Tumor News and Research

RSS

Novel approach using Listeria bacteria shows promise against metastatic pancreatic cancer

Researchers at Albert Einstein College of Medicine of Yeshiva University have developed a therapy for pancreatic cancer that uses Listeria bacteria to selectively infect tumor cells and deliver radioisotopes into them.

25 Apr 2013

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

XBiotech announced today enrollment of the first patient into its Phase III trial of Xilonix. The Pivotal study is designed to improve health and survival of late stage colorectal cancer patients with associated cachexia.

25 Apr 2013

FDA designates Merck's lambrolizumab as Breakthrough Therapy for advanced melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma.

25 Apr 2013

Individuals with MEN1 are at increased risk of developing neuroendocrine tumors

A mutation in a protein called menin causes a hereditary cancer syndrome called MEN1 (multiple endocrine neoplasia type 1).

25 Apr 2013

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Hospital for Special Surgery in New York City has received a $5.6 million grant from The Tow Foundation to establish the Hospital for Special Surgery Genomics Center.

25 Apr 2013

Promising development for women with triple-negative breast cancer

Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.

24 Apr 2013

Research project to identify mechanisms underlying effects of cancer drug interferon-α

The immune system plays a decisive role in the fight against tumor cells. However, when tumor cells themselves prevent activation of the immune system, the immune system fails to destroy cancer cells.

24 Apr 2013

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.

24 Apr 2013

Methodist Hospital will soon have new brain and pituitary tumor treatment center

Brain and pituitary tumor patients will soon have access to a state-of-the-art facility at The Methodist Hospital, a result of a $10 million dollar commitment from a Houston oil executive.

24 Apr 2013

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations.

23 Apr 2013

Individual cancer cells in blood stream are responsible for metastases in breast cancer patients

Individual cancer cells that break away from the original tumor and circulate through the blood stream are considered responsible for the development of metastases. These dreaded secondary tumors are the main cause of cancer-related deaths.

23 Apr 2013

Researchers find deficiency in anti-tumor protein can delay DNA repair after radiation treatment

Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.

23 Apr 2013

Researchers explore new technique to determine the activity of different calcium channels in cancer cells

Two Wayne State University researchers are working on a technique that could lead to easier, faster identification of cancer tumors that can be effectively treated by calcium channel-based therapies.

23 Apr 2013

New screening method detects ovarian cancer by examining neighboring cells

Pioneering biophotonics technology developed at Northwestern University is the first screening method to detect the early presence of ovarian cancer in humans by examining cells easily brushed from the neighboring cervix or uterus, not the ovaries themselves.

23 Apr 2013

Researchers find tumors with ALK rearrangements can harbor additional mutations

The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment.

23 Apr 2013

OHSU, Intel team up to develop technologies to make personalized genomic analysis faster

Oregon Health & Science University and Intel Corp. are teaming up to develop next-generation computing technologies that advance the field of personalized medicine by dramatically increasing the speed, precision and cost-effectiveness of analyzing a patient's individual genetic profile.

23 Apr 2013

Senesco completes cohort 2 in Phase 1b/2a clinical study of SNS01-T

Senesco Technologies, Inc. reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T.

23 Apr 2013

NKI-AVL joins research consortium to develop MRI-guided radiation therapy system for cancer care

Elekta and Royal Philips Electronics announced today that The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital has signed an agreement to join a research group to advance the development of ground-breaking image-guided treatment technology for cancer care.

From Elekta 23 Apr 2013

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer coordinated by the Brown University Oncology Research Group (BrUOG).

22 Apr 2013

Study identifies potential drug targets that interfere with cancer metabolism

A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer.

22 Apr 2013

Tumor News and Research

Novel approach using Listeria bacteria shows promise against metastatic pancreatic cancer

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

FDA designates Merck's lambrolizumab as Breakthrough Therapy for advanced melanoma

Individuals with MEN1 are at increased risk of developing neuroendocrine tumors

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Promising development for women with triple-negative breast cancer

Research project to identify mechanisms underlying effects of cancer drug interferon-α

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

Methodist Hospital will soon have new brain and pituitary tumor treatment center

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

Individual cancer cells in blood stream are responsible for metastases in breast cancer patients

Researchers find deficiency in anti-tumor protein can delay DNA repair after radiation treatment

Researchers explore new technique to determine the activity of different calcium channels in cancer cells

New screening method detects ovarian cancer by examining neighboring cells

Researchers find tumors with ALK rearrangements can harbor additional mutations

OHSU, Intel team up to develop technologies to make personalized genomic analysis faster

Senesco completes cohort 2 in Phase 1b/2a clinical study of SNS01-T

NKI-AVL joins research consortium to develop MRI-guided radiation therapy system for cancer care

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Study identifies potential drug targets that interfere with cancer metabolism

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News